their expression in benign and malignant well-differentiated and poorly differentiated components of 88 prostates with prostatic adenocarcinomas , and in 25 metastases , was evaluated using polyclonal antibodies developed against these antigens .
C0033572
prostates
C0007112
prostatic adenocarcinomas